Medical Affairs

“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined outpatient regimen aimed at accelerating enrollment and regulatory review in the Phase II ALPHA3 trial (NCT06500273).

AI influencers represent the cutting edge of digital storytelling. But when applied to pharmaceutical marketing, innovation must be balanced with integrity.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

Marketing and sales personnel who leverage the expertise and insights of MedAffairs can often have better success.

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.